TNF Pharmaceuticals, Inc.
TNFA
$0.0642
-$0.0109-14.51%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.10M | 4.56M | 5.22M | 6.11M | 6.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.36M | 8.35M | 8.66M | 11.38M | 13.40M |
| Operating Income | -8.36M | -8.35M | -8.66M | -11.38M | -13.40M |
| Income Before Tax | -6.91M | -14.68M | -23.36M | -23.66M | -17.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.91 | -14.68 | -23.36 | -23.66 | -17.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.91M | -14.68M | -23.36M | -23.66M | -17.69M |
| EBIT | -8.36M | -8.35M | -8.66M | -11.38M | -13.40M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.74 | -7.11 | -11.88 | -13.51 | -10.56 |
| Normalized Basic EPS | -1.18 | -3.73 | -6.46 | -6.84 | -4.62 |
| EPS Diluted | -2.74 | -7.11 | -11.88 | -13.51 | -12.03 |
| Normalized Diluted EPS | -1.18 | -3.73 | -6.46 | -6.84 | -5.97 |
| Average Basic Shares Outstanding | 26.34M | 12.92M | 9.71M | 8.63M | 7.78M |
| Average Diluted Shares Outstanding | 26.34M | 12.92M | 9.71M | 8.63M | 14.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -19.62% | -9.24% | -11.32% | -11.58% | -15.50% |